Key result
High intra-plaque vascularization links to ~284% higher major cardiovascular events risk in type 2 diabetes.
Why the study?
Patients with T2DM and no significant carotid stenosis are often considered at moderate cardiovascular risk despite potentially harboring biologically active plaques, making the prognostic role of CEUS-detected intra-plaque vascularization and SGLT2i effects relevant.
Does SGLT2 inhibitor therapy reduce major adverse cardiovascular events in asymptomatic type 2 diabetes patients with non-significant carotid atherosclerosis?
Cohort (n=251)
Single-blind
No
Does SGLT2 inhibitor therapy reduce major adverse cardiovascular events in asymptomatic type 2 diabetes patients with non-significant carotid atherosclerosis?
CEUS-detected intra-plaque vascularization predicts cardiovascular events in asymptomatic T2DM patients, and SGLT2 inhibitor therapy significantly reduces this risk, particularly in those with highly vascularized plaques.
Answers are grounded in this paper and cite their sources.
May refine MACE risk stratification by CEUS in asymptomatic T2DM; leaves open whether SGLT2 inhibitors modify outcomes in high-vascularization plaques.
Aims Patients with type 2 diabetes mellitus (T2DM) and no significant carotid stenosis are often considered at moderate cardiovascular risk. However, some may harbour biologically active plaques. Intra-plaque vascularization (IPV), detectable in contrast-enhanced ultrasound (CEUS), reflects plaque vulnerability and may enhance risk stratification. We assessed the prognostic value of CEUS-derived IPV and the effects of SGLT2 inhibitors (SGLT2i) on cardiovascular outcomes and inflammatory markers. Methods and results In this 6-year prospective cohort study, 251 asymptomatic T2DM patients with carotid atherosclerosis <50% stenosis were enrolled. IPV was quantified by CEUS and stratified by tertiles. The primary endpoint was major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke, or heart failure hospitalization). Secondary endpoints included changes in VEGF, IL-6, and TNF-α levels. Patients were also stratified by chronic SGLT2i use. High IPV was associated with greater MACE incidence (32.5%) compared with low IPV (7.4%; HR 3.84, 95% CI 1.89–7.78; P < 0.001). SGLT2i-treated patients showed reduced MACE incidence (12.1% vs. 26.3%, P = 0.004), particularly in the high-IPV subgroup (23.1% vs. 38.9%; HR 0.48, 95% CI 0.25–0.91; P = 0.026). Treatment was also linked to significant VEGF (−52.4 vs. −18.6 pg/mL) and IL-6 (−1.9 vs. −0.6 pg/mL) reductions (P < 0.001 for both). Conclusion CEUS-detected IPV predicts cardiovascular events in T2DM patients without significant stenosis. SGLT2i may reduce risk by modulating plaque inflammation and angiogenesis. CEUS combined with biomarker profiling may support personalized prevention strategies in diabetes.
No takes yet. Share an insight, caveat, or question.
Marfella et al. (2025) conducted a cohort in Type 2 diabetes mellitus with non-significant carotid atherosclerotic stenosis (n=251). High intra-plaque vascularization (IPV) vs. Low intra-plaque vascularization (IPV) was evaluated on Major adverse cardiovascular events (MACE: CV death, non-fatal MI, non-fatal stroke, or heart failure hospitalization) (HR 3.84, 95% CI 1.89-7.78, p=<0.001). High intra-plaque vascularization detected by contrast-enhanced ultrasound was associated with a higher incidence of major adverse cardiovascular events compared to low vascularization in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: